Search Results
192 results found-
While immune response is the standard used Seqirus continued its support for the Pandemic Influenza in the regulatory approval of vaccines, the panel found that Preparedness Framework operated by WHO, which aims to immune response is insufficient evidence to support claims build pandemic preparedness capacity in low and middle- for the degree, breadth or duration of clinical effect.
https://www.csl.com/-/media/csl/documents/annual-report-docs/csl-ltd-annual-report-2020-full.pdf -
Seqirus is a major contributor to the prevention of influenza globally and a transcontinental partner in pandemic preparedness.
https://www.csl.com/-/media/csl/documents/csl-statement-on-modern-slavery-2021.pdf -
There is strong for pandemic preparedness with new in-licensing agreements for hay fever The most significant driver of growth was scientific rationale to suggest that governments around the world.
https://www.csl.com/-/media/csl/documents/annual-report-docs/csl-ltd-annual-report-2018-full.pdf -
Seqirus is a major contributor to the prevention of influenza globally and a transcontinental partner in pandemic preparedness.
https://www.csl.com/-/media/shared/documents/seqirus-disclosures/disclosures-2020/csl-statement-on-modern-slavery-2020.pdf -
As a leading influenza products in the industry for treating rare and serious diseases vaccine provider in the world, Seqirus is a major contributor such as haemophilia, von Willebrand disease (vWD), primary to the prevention of influenza globally and a transcontinental immune deficiencies (PI), chronic inflammatory demyelinating partner in pandemic preparedness.
https://www.csl.com/-/media/csl/tax-transparency-reports/csl-limited-tax-transparency-report-2021.pdf -
Global R&D activities From our emerging family of recombinant influenza vaccine for Northern and Southern support CSL's existing licensed products and coagulation products that aim to dramatically Hemisphere markets and a transcontinental development of new therapies that align with improve the lives of patients with bleeding partner in pandemic preparedness and WWW.
https://www.csl.com/-/media/csl/corporate-responsibility-reports/csl-limited-corporate-responsibility-report-2017.pdf -
As part of our contribution to protect public health worldwide, Seqirus continued its support for the Pandemic Influenza Preparedness Framework operated by WHO, which aims to build pandemic preparedness capacity in low and middle- income countries.
https://www.csl.com/-/media/csl/documents/annual-report-docs/csl-ltd-annual-report-2019-full.pdf -
With extensive activities support innovation in new products and research and production expertise and manufacturing technology, improved products and manufacturing plants in the US, UK, and Australia, Seqirus is a expertise to ensure our continued growth and transcontinental partner in pandemic preparedness commitment to fulfill patient's needs.
https://www.csl.com/-/media/csl/tax-transparency-reports/csl-limited-tax-transparency-report-2018.pdf -
fledgling CSL swung into action, producing company was invited to join a new committee emerging cell-based technology as part of In 2015, CSL acquired the Novartis influenza three million doses of a mixed bacterial vaccine to advise the Australian Government on the pandemic preparedness plans.
https://www.csl.com/-/media/csl/documents/annual-report-docs/csl-ltd-annual-report-2016-full.pdf -
We are a major supplier of influenza vaccine for Northern and Southern Hemisphere markets, and a transcontinental partner in pandemic preparedness and response.
https://www.csl.com/-/media/csl/tax-transparency-reports/csl-limited-tax-transparency-report-2017.pdf